Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Non-Current Assets (2019 - 2025)

aTYR PHARMA (ATYR) has disclosed Non-Current Assets for 7 consecutive years, with $12.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Assets fell 14.18% year-over-year to $12.8 million, compared with a TTM value of $54.4 million through Dec 2025, down 12.44%, and an annual FY2025 reading of $12.8 million, down 14.18% over the prior year.
  • Non-Current Assets was $12.8 million for Q4 2025 at aTYR PHARMA, down from $13.6 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $18.3 million in Q2 2023 and bottomed at $1.7 million in Q1 2022.
  • Average Non-Current Assets over 5 years is $11.4 million, with a median of $14.0 million recorded in 2025.
  • The sharpest move saw Non-Current Assets tumbled 44.59% in 2022, then skyrocketed 948.28% in 2023.
  • Year by year, Non-Current Assets stood at $2.0 million in 2021, then soared by 657.88% to $14.9 million in 2022, then rose by 18.41% to $17.7 million in 2023, then decreased by 15.77% to $14.9 million in 2024, then fell by 14.18% to $12.8 million in 2025.
  • Business Quant data shows Non-Current Assets for ATYR at $12.8 million in Q4 2025, $13.6 million in Q3 2025, and $14.0 million in Q2 2025.